| [1] |
He J, Chen WQ. Chinese Journal of tumor registration, 2012[M]. Beijing: Military Medical Science Press, 2012: 28-39. [赫捷, 陈 万清. 2012中国肿瘤登记年报[M]. 北京: 军事医学科学出版社, 20 12: 28-39.]
|
| [2] |
Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer Genome Landscapes[J]. Science, 2013, 339(6127): 1546-58.
|
| [3] |
Yuan X, Wu H, Han N, et al. Notch signaling and EMT in nonsmall cell lung cancer: biological significance and therapeutic application[J]. J Hematol Oncol, 2014, 7: 87.
|
| [4] |
D‘Antonio C, Passaro A, Gori B, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies[J]. Ther Adv Med Oncol, 2014, 6(3): 101-14.
|
| [5] |
Mountain CF. Staging classification of lung cancer: a critical evaluation[J]. Clin Chest Med, 2002, 23(1): 103-21.
|
| [6] |
Naruke T, Goya T, Tsuchiya R, et al. Prognosis and survival in resected lung carcinoma based on the new international staging system[J]. J Thorac Cardiovasc Surg, 1988, 96(3): 440-7.
|
| [7] |
Zhan P, Wang J, Zhang Y, et al. CYP2E1 RsaⅠ/PstⅠ polymorphism is associated with lung cancer risk among Asians[J]. Lung Cancer, 20 10, 69(1): 19-25.
|
| [8] |
Bartsch H, Nair U, Risch A, et al. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobaccorelated cancers[J]. Cancer Epidemiol Biomarkers Prev, 2000, 9(1): 3-28.
|
| [9] |
Jazieh AR, Hussain M, Howington JA, et al. Prognostic factors in patients with surgically resected stagesⅠandⅡnon-small cell lung cancer[J]. Ann Thorac Surg, 2000, 70(4): 1168-71.
|
| [10] |
Raunio H, Hakkola J, Hukkanen J, et al. Expression of xenobioticmetabolizing CYPs in human pulmonary tissue[J]. Exp Toxicol Pathol, 1999, 51(4-5): 412-7.
|
| [11] |
Jiang O, Zhou R, Wu D, et al. CYP2E1 polymorphisms and colorectal cancer risk: a HuGE systematic review and Metaanalysis[ J] Tumor Biol, 2013, 34(2): 1215-24.
|
| [12] |
Oyama T, Sugio K, Uramoto H, et al. Increased cytochrome P450 and aryl hydrocarbon receptor in bronchial epithelium of heavy smokers with non-small cell lung carcinoma carries a poor prognosis[J]. Front Biosci, 2007, 12: 4497-503.
|
| [13] |
Marchand LL, Wilkinson GR, Wilkens LR. Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone[J]. Cancer Epidemiol Biomarkers Prev, 1999, 8(6): 495-500.
|
| [14] |
Olivieri EH, da Silva SD, Mendona FF, et al. CYP1A2*1C, CYP2E1*5B, and GSTM1 polymorphisms are predictors of risk and poor outcome in head and neck squamous cell carcinoma patients[J]. Oral Oncol, 2009, 45(9): e73-9.
|
| [15] |
Feng J, Pan X, Yu J, et al. Functional PstI/RsaI polymorphism in CYP2E1 is associated with the development, progression and poor outcome of gastric cancer[J]. PLoS One, 2012, 7(9): e44478.
|
| [16] |
Li WY, Yue WT, Yang XH, et al. Relationship between the Genetic Polymorphisms of PhaseⅠandⅡDrug-metaboliz ing Enzymes, as well as the Outcome of Chemotherapy in Advanced Non-small Cell Lung Cancer[J]. Zhongguo Fei Ai Za Zhi, 2011, 14(11): 85 8-64. [李伟英, 岳文涛, 杨学惠, 等. Ⅰ、Ⅱ相药物代谢酶遗 传多态性与晚期非小细胞肺癌化疗疗效的关系[J]. 中国肺癌杂 志, 2011, 14(11): 858-64.]
|
| [17] |
Haque AK, Au W, Ca j a s -Sa l a z a r N, e t al . CYP2E1 polymorphism,cigarette smoking,p53 expression,and survival in non-small cell lung cancer: a long term follow-up study[J]. Appl Immunohistochem Mol Morphol, 2004, 12(4): 315-22.
|
| [18] |
Hanagiri T, Sugio K, Uramoto H, et al. Gender difference as a prognostic factor in patients undergoing resection of non-small cell lung cancer[J]. Surg Today, 2007, 37(7): 546-51.
|
| [19] |
Yu C, Sun XH, Zhao JB, et al. Prognostic factors of advanced non small cell lung cancer[J]. Zhonghua Lin Chuang Yi Shi Za Zhi(Dian Zi Ban), 2011, 5(9): 2691-6. [于晨, 孙秀华, 赵金波, 等. 晚期非小细胞肺癌预后因素的回顾性研究[J]. 中华临床医师杂 志(电子版), 2011, 5(9): 2691-6.]
|
| [20] |
Yuan JM, Butler LM, Stepanov I, et al. Urinary tobacco smokeconstituent biomarkers for assessing risk of lung cancer[J]. Cancer Res, 2014, 74(2): 401-11.
|
下载:
